Patient
SITE011-0083
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE011 (ITA) (Dr. Jansen)
consented 2025-11-30
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 6
Grade 1 Nausea — outcome: UNKNOWN; onset 2023-02-12 (study day 249); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-22 (study day 197); relationship: not assessed
Grade 2 Neutropenia — outcome: UNKNOWN; onset 2022-11-01 (study day 146); relationship: NOT RELATED
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-24 (study day 138); relationship: RELATED
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-08-01 (study day 54); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-31 (study day 53); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.